-
Japanese Journal of Pharmacology Sep 1998A novel non-peptide bradykinin B2-receptor agonist, FR190997 (8-[2,6-dichloro-3-[N-[(E)4-(N-methylcarbamoyl)cinnamidoacetyl+...
A novel non-peptide bradykinin B2-receptor agonist, FR190997 (8-[2,6-dichloro-3-[N-[(E)4-(N-methylcarbamoyl)cinnamidoacetyl+ ++]-N-methylamino]benzyloxy]-2-methyl-4-(2-pyridylmethoxy)quinolin e), induced dose-dependent and longer-lasting swelling than bradykinin in the mouse paw. The swelling, peaking around 30 min, was suppressed dose-dependently by intraperitoneal administration of FR173657, a novel non-peptide B2-receptor antagonist. A known B2-antagonist, Hoe 140, also significantly suppressed this edema. The result indicates that the novel B2-agonist FR190997, being more stable than bradykinin, could induce plasma exudation locally in mice via the B2-receptor as a substitute for bradykinin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bradykinin; Bradykinin Receptor Antagonists; Dose-Response Relationship, Drug; Edema; Foot; Hindlimb; Male; Mice; Mice, Inbred ICR; Quinolines; Receptors, Bradykinin
PubMed: 9804073
DOI: 10.1254/jjp.78.109 -
Annals of Internal Medicine Oct 1985Two patients had recurrent facial edema and peripheral blood eosinophilia. One patient showed a marked increase in the serum level of the eosinophil granule major basic...
Two patients had recurrent facial edema and peripheral blood eosinophilia. One patient showed a marked increase in the serum level of the eosinophil granule major basic protein. In both patients, skin biopsy samples showed nonspecific mononuclear cell inflammation with few eosinophils. However, immunofluorescence staining showed extracellular localization of the major basic protein within the dermis, similar to that previously shown in chronic urticaria and the recently described syndrome of episodic angioedema with eosinophilia. These observations provide further evidence that degranulation of eosinophils occurs in the skin and suggest that eosinophil mediators may play a role in the development of cutaneous edema.
Topics: Blood Proteins; Cytoplasmic Granules; Edema; Eosinophil Granule Proteins; Eosinophilia; Eosinophils; Face; Female; Fluorescent Antibody Technique; Humans; Male; Middle Aged; Ribonucleases; Skin
PubMed: 3898950
DOI: 10.7326/0003-4819-103-4-503 -
British Journal of Community Nursing Mar 2024There is an established link between hypothyroidism and leg oedema. This article presents a case study of a female known to have an underactive thyroid gland who...
There is an established link between hypothyroidism and leg oedema. This article presents a case study of a female known to have an underactive thyroid gland who developed symptoms and was referred to a local Lindsay Leg Club.
Topics: Female; Humans; Leg; Hypothyroidism; Edema; Neck
PubMed: 38478421
DOI: 10.12968/bjcn.2024.29.Sup3.S40 -
Nihon Rinsho. Japanese Journal of... Jan 2005Edema is defined as the condition in which intraluminal lymph fluid components leak into the tissues and the interstitium fluid is abnormally increased. At the site of... (Review)
Review
Edema is defined as the condition in which intraluminal lymph fluid components leak into the tissues and the interstitium fluid is abnormally increased. At the site of edema, toxication, allergy or inflammation occasionally occurs. This paper will focus on local skin and mucosal edema. Toxic edema is locally caused by intake of industrial goods or medical products (pharmaceuticals). Like urticaria, allergic edema is attributed to the increased vascular permeability caused by a chemical mediator. Inflammatory edema is the state in which increased inflammatory reaction in local skin causes increases in osmotic pressure of the tissues and metabolism and then inflammatory effusion accumulate there. It includes burn and cellulites.
Topics: Edema; Humans; Hypersensitivity; Inflammation; Skin
PubMed: 15675328
DOI: No ID Found -
Revista Da Sociedade Brasileira de... 1999Edema, which is commonly described as a symptom of reactional states, may occur during the course of leprosy. Both diagnosis and adequate treatment measures are often...
Edema, which is commonly described as a symptom of reactional states, may occur during the course of leprosy. Both diagnosis and adequate treatment measures are often difficult to achieve and failure to do so may result in permanent damage to the lower limbs. In a one-year follow-up study of leprosy patients--ten multibacillary and one paucibacillary--who had been submitted to a clinical protocol for diagnosis and pathological classification, a clinical pattern of localized and/or systemic edema was observed. Among these patients, five simultaneously presented other symptoms related to reactional states, 4 were diagnosed as Type I, and one as Type II. On the other hand, while three of the patients did not present reaction at the time when edema was diagnosed, they did develop some aspects of reactional disease later on (two had neuritis e one had Type I reaction). The edemas that preceded or were associated with reactional episodes showed clinical regression as a result of specific treatment against reactions (corticosteroids and/or pentoxifylline and/or thalidomide) in the absence of another treatment normally used for edemas. Although these data need to be confirmed by controlled studies, they strongly suggest that immunological mechanisms are involved in the physiopathology of edema in leprosy.
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Edema; Erythema Nodosum; Female; Humans; Leprostatic Agents; Leprosy, Lepromatous; Leprosy, Tuberculoid; Male; Middle Aged; Time Factors; Treatment Outcome
PubMed: 10228362
DOI: 10.1590/s0037-86821999000200003 -
Angiology Jan 2000An International Task Force made up of a panel of 16 experts has reviewed and objectively evaluated all aspects of chronic venous disease of the leg (CVDL). All... (Meta-Analysis)
Meta-Analysis
An International Task Force made up of a panel of 16 experts has reviewed and objectively evaluated all aspects of chronic venous disease of the leg (CVDL). All available publications on CVDL from 1983 to 1997 were identified through computerized search in Medline and by a manual search. Next, three different screenings were performed in order to select only relevant papers providing a level of scientific evidence that was considered moderate to strong. Final conclusions and further therapeutic recommendations were made based on these publications. Medication, compression, local therapy, sclerotherapy, and surgery are the accepted available therapeutic options for CVDL. For edema, the following recommendations can be made: edema is an early sign of CVDL, but before starting any treatment, nonvenous causes of edema should be excluded. Medication and compression are the therapeutic options for edema that are accepted by the Task Force. Evaluation of their efficacy is based on objective measures of edema. Several well-conducted, placebo-controlled trials have shown efficacy of drugs such as micronized purified flavonoid fraction, rutosides, calcium dobesilate, and coumarin rutin. Graduated compression stockings have been shown to be effective; compression needs to be exerted at least at 35 mm Hg. Bandages, if properly applied, both fixed and stretched, can produce favorable results. Sclerotherapy or surgery is not indicated unless there is saphenofemoral or saphenopopliteal reflux. In the absence of such reflux or following deep venous thrombosis, there is no evidence to support sclerotherapy or surgery.
Topics: Anticoagulants; Bandages; Calcium Dobesilate; Cardiovascular Agents; Chronic Disease; Controlled Clinical Trials as Topic; Coumarins; Diosmin; Edema; Femoral Vein; Hemostatics; Humans; Leg; Placebos; Rutin; Saphenous Vein; Sclerotherapy; Vasodilator Agents; Venous Insufficiency; Venous Thrombosis
PubMed: 10667638
DOI: 10.1177/000331970005100104 -
Wound Repair and Regeneration :... 2011The local pathogenesis of interstitial edema in burns is incompletely understood. This ex vivo study investigates the forces mediating water-transfer in and out of...
The local pathogenesis of interstitial edema in burns is incompletely understood. This ex vivo study investigates the forces mediating water-transfer in and out of heat-denatured interstitial matrix. Experimentally, full-thickness dermal samples are heated progressively to disrupt glycosaminoglycans, kill cells, and denature collagen under conditions that prevent water loss/gain; subsequently, a battery of complementary techniques including among others, high-resolution magnetic resonance imaging, equilibrium vapor pressure and osmotic stress are used to compare water-potential parameters of nonheated and heated dermis. The hydration potential (HP) determined by osmotic stress is a measure of the total water-potential defined empirically as the pressure at which no net water influx/efflux into/from the dermis is detected. Results show that after heat denaturation, the HP, the intensity of T2-weighed magnetic resonance images, and the vapor pressure increase indicating higher water activity and necessarily, smaller contributions from colloidosmotic forces to fluid influx in burned relative to healthy dermis. Concomitant increases in HP and in water activity implicate local changes in interfacial and metabolic energy as the source of excess fluid-transfer potential. These ex vivo findings also show that these additional forces contributing to abnormal fluid-transfer in burned skin develop independently of inflammatory and systemic hydrodynamic responses.
Topics: Animals; Burns; Edema; Extracellular Fluid; Humans; Magnetic Resonance Imaging; Osmotic Pressure; Skin; Swine
PubMed: 21518093
DOI: 10.1111/j.1524-475X.2011.00689.x -
AJR. American Journal of Roentgenology Aug 2003Our aim was to determine the occurrence of bone marrow edema and joint effusion and their relationship to pain in patients with osteonecrosis of the femoral head on the...
OBJECTIVE
Our aim was to determine the occurrence of bone marrow edema and joint effusion and their relationship to pain in patients with osteonecrosis of the femoral head on the basis of MR imaging.
MATERIALS AND METHODS
There were 71 patients with osteonecrosis of the femoral head based on characteristic radiographic and MR imaging findings. All patients had surgical confirmation of the disease. Both hips were affected with osteonecrosis in 39 patients, whereas only one hip was involved in 31 patients. The last patient underwent an arthroplasty of one hip during the study and had only one hip imaged. We evaluated a total of 110 hips in this study, of which 98 were painful. We staged osteonecrosis of the femoral head, using the classification of Steinberg et al. The 31 unaffected hips served as controls. Bone marrow edema and joint fluid were evaluated on MR images. Bone marrow edema was defined as an ill-defined area of low signal intensity on T1-weighted images with corresponding high signal intensity on T2-weighted or inversion recovery images localizing to the femoral head, neck, and intertrochanteric region. The amount of joint fluid was graded from 0 to 3.
RESULTS
The peak of bone marrow edema occurred in stage III disease (72%); its odds ratio was seven times greater than that for stage I osteonecrotic hips. Effusions of a grade greater than or equal to 2 were seen most often in stage III disease (92%), compared with 10% in the control hips. With an effusion, bone marrow edema was 12.6 times greater when the hip was painful than when it was not.
CONCLUSION
Both bone marrow edema and joint effusions existed with a peak occurrence in stage III disease. Bone marrow edema seems to have a stronger association with pain than does joint effusion in osteonecrosis of the femoral head.
Topics: Adolescent; Adult; Aged; Arthralgia; Bone Marrow; Edema; Female; Femur Head; Femur Head Necrosis; Hip Joint; Humans; Hydrarthrosis; Magnetic Resonance Imaging; Male; Middle Aged
PubMed: 12876044
DOI: 10.2214/ajr.181.2.1810545 -
Biomolecules Nov 2022A novel peptide AnmTX Sco 9a-1 with the β-hairpin fold was isolated from the swimming sea anemone (Actinostolidae family). The peptide consists of 28 amino acid...
A novel peptide AnmTX Sco 9a-1 with the β-hairpin fold was isolated from the swimming sea anemone (Actinostolidae family). The peptide consists of 28 amino acid residues, including modified hydroxyproline residue, and its measured molecular mass is 2960 Da. The peptide was not toxic on mice; however, it stimulated their exploratory motivation and active search behavior, and demonstrated an anti-anxiety effect. AnmTX Sco 9a-1 at doses of 0.1 and 1 mg/kg reduced the volume of edema during 24 h better than the nonsteroidal anti-inflammatory drug, Diclofenac, at dose of 1 mg/kg in a model of acute local λ-carrageenan-induced inflammation. ELISA analysis of the animal's blood showed that peptide at a dose of 1 mg/kg reduced the content of tumor necrosis factor-α (TNF-α), a pro-inflammatory mediator responsible in the edema development, up to the level of TNF-α in the intact group. Besides, AnmTX Sco 9a-1 demonstrated a significant analgesic effect on acute pain sensitivity in the carrageenan-induced thermal hyperalgesia model at doses of 0.1 and 1 mg/kg. Activity of AnmTX Sco 9a-1 was shown not to be associated with modulation of nociceptive ASIC channels.
Topics: Animals; Mice; Anti-Inflammatory Agents; Edema; Peptides; Sea Anemones; Tumor Necrosis Factor-alpha
PubMed: 36421718
DOI: 10.3390/biom12111705 -
Biomedical Sciences Instrumentation 2006Energy medicine has existed for centuries in some parts of the world, but in recent years, western health care practitioners have taken a heightened interest in these...
Energy medicine has existed for centuries in some parts of the world, but in recent years, western health care practitioners have taken a heightened interest in these therapies. Treatment by use of pulsed magnetic fields (PMF) is currently being explored in both chronic and inflammatory diseases such as cancer, epilepsy, psoriasis, rheumatoid arthritis, and tendinitis. In the U.S., PMFs have already been approved for use in treatment of bone fractures in humans and clinical trials have been conducted for lower back pain. This study presents a summary of the therapeutic potential of a localized PMF treatment for tendinitis using the Softpulse III system. This system has been used to accelerate wound healing and soft tissue swelling. It generates a specific PMF that induces an electrical field within the tendon. This induced electrical field is thought to influence the healing process by affecting the inflammatory cells that line the tendon sheath. In this study, we have used an established model of tendinitis along with a validated method for appraising edema and gait (Achilles' Functional Index), to test the hypothesis that the proposed PMF signal is effective in reducing the indicators of acute tendinitis injury. These experiments were approved by the Institutional Animal Care and Use Committee. Our findings suggest a role for the treatment of soft tissue injury using the Softpulse III therapeutic device. The symbolic stand point of PMF treatments is to push the need for a revolutionary leap, from the more dominant pharmaceutical and surgical interventions, to the advanced applications of non-invasive therapies that would minimize the medicinal risk of side effects, and eliminate the risk of complicated drug interactions.
Topics: Animals; Edema; Electric Stimulation Therapy; Female; Gait; Magnetics; Rats; Rats, Sprague-Dawley; Recovery of Function; Tendinopathy; Treatment Outcome
PubMed: 16817646
DOI: No ID Found